Search the Newsreel

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items. This …

NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

NRXP Q2'26 Earnings: EPS estimate is (0.11) USD

NRX Pharmaceuticals, Inc. (NRXP) is scheduled to announce its Q2'26 earnings on August 17th. The company anticipates a revenue of $1.33 million and an earnings per share (EPS) of ($0.11) for the quarter. This article provides a historical comparison of reported and estimated revenue …

H.C. Wainwright reiterates NRx Pharmaceuticals stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $45.00 price target for NRx Pharmaceuticals (NASDAQ:NRXP) following a positive regulatory update from the FDA regarding its KETAFREE abbreviated New Drug Application. The FDA found no major deficiencies related to the drug components, with the …

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals (NASDAQ: NRXP) has completed the FDA's first-cycle review for its preservative-free ketamine ANDA, with the only remaining concern being a potential issue with the vial's Luer lock tip. The company has submitted a manufacturer attestation to address this and is expanding its …

NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Monday

NRx Pharmaceuticals (NRXP) is projected to release its Q2 2026 earnings before the market opens on Monday, August 17th. Analysts anticipate a loss of $0.09 per share and revenues of $1.33 million. In the previous quarter, the company reported a smaller loss than expected …

NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History

NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The article provides current stock performance data, including a 15.86% increase at close, and a company overview highlighting its drug pipeline and financial metrics. It also …

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss …

BTIG Research Cuts NRx Pharmaceuticals (NASDAQ:NRXP) Price Target to $10.00

A vial used in products that shipped 11.9M doses remains in NRx's FDA review

NRx Pharmaceuticals announced that the FDA completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine, finding no major drug-related deficiencies. The only remaining issue is a packaging-related Major Deficiency concerning the luer lock vial tip, which NRx …

NRx Pharma rises on FDA review of ketamine ANDA (NRXP:NASDAQ)

NRx Pharmaceuticals (NRXP) stock rose on Friday after the company announced that the FDA completed its initial review of its marketing application for its preservative-free ketamine product. The FDA did not identify any major deficiencies in the application, which led to the increase in …

NRx Pharmaceuticals completes FDA first-cycle ANDA review

NRx Pharmaceuticals Inc. announced that the FDA completed its first-cycle review of the company’s Abbreviated New Drug Application (ANDA) for preservative-free ketamine. While no major deficiencies were found regarding the drug product itself, the FDA identified one major deficiency related to manufacturer certification for …

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will host a conference call and Q&A session on Monday, August 10, 2026, at 8:30 a.m. ET. The call will discuss the FDA's first-cycle review of the Company's ANDA for preservative-free ketamine, which was announced earlier the same day. Key …

NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-AUG-2026.

Certain warrants of NRx Pharmaceuticals, Inc. will be under a 61-day lock-up agreement, starting from June 3, 2026, and ending on August 3, 2026. This agreement restricts executive officers, directors, and the company itself from selling or disposing of common stock or convertible securities …

NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of NRX Pharmaceuticals Inc (NRXP), detailing its current stock price momentum, support and resistance levels, and indicator and moving average readings. It notes that NRXP's stock price is trading between a resistance level of 4.23 and a support …

NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of NRX Pharmaceuticals Inc (NRXP), highlighting its current financial score of 7.81, which ranks 83 out of 385 in the Biotechnology & Medical Research industry. The analysis indicates the company's financial status is weak with low operating …

NRX Pharmaceuticals Market Sentiment

This article analyzes the market sentiment for NRX Pharmaceuticals (NRXP), focusing on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from seven analysts with a significant average price target upside, and notes a 13.2% declining short float. The …

NRX Pharmaceuticals Inc (NRXP) Institutional Confidence

This article provides details on NRX Pharmaceuticals Inc (NRXP)'s institutional confidence score and shareholding information. It lists several institutional shareholders, their shareholdings, and the percentage change in their holdings. The institutional confidence score for NRXP is 3.00, remaining unchanged from the previous score.

NRX Pharmaceuticals Inc (NRXP) Cash Flow

This article provides a detailed cash flow statement for NRX Pharmaceuticals Inc (NRXP), offering both quarterly and annual data with year-over-year comparisons for various cash flow components. It includes breakdowns for operating, investing, and financing activities, along with frequently asked questions defining key cash …

NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of NRX Pharmaceuticals Inc (NRXP), listing major individual and institutional holders and their respective proportions. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and provides a historical overview of institutional holdings and recent shareholder activity. …

NRXP|NRX Pharmaceuticals Inc|Price:3.340|Chg%:-0.020

TradingKey

This page provides a detailed quarterly and annual income statement for NRX Pharmaceuticals Inc (NRXP), including financial data from FY2017Q3 through FY2026Q1. It covers metrics such as total revenue, operating expenses, net income, and earnings per share, alongside FAQs to help users understand the …

NRX Pharmaceuticals, Inc. Revenue Breakdown – FWB:B1Q

This article provides a financial overview of NRX Pharmaceuticals, Inc. (FWB:B1Q) on TradingView. It indicates that the market is closed with no recent trades and details the company's financials, including statements, statistics, dividends, earnings, and segment performance. The page also offers various market data …

NRX Pharmaceuticals Inc (B1Q.HM) stock major holders

This article provides a brief overview of NRX Pharmaceuticals Inc (B1Q.HM) stock, focusing on its major holders. It shows the current stock price, its daily change, and outlines key holder-related data such as percentage of shares held by insiders and institutions. The content appears …

Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, is anticipated to reach profitability by 2027, according to analysts. The company, currently with a US$181m market cap, posted a US$25m loss in its last trailing-twelve-month period. Analysts project a significant annual growth rate of 56% …

NRXP Forecast — Price Target — Prediction for 2027

NRX Pharmaceuticals (NRXP) Q1 2026 Earnings: Significant EPS Miss but Stock Gains on Operational Updates - Profit Announcement

NRx Pharmaceuticals Earnings Call Maps 2026 Catalyst Path

NRx (NRXP) Q1 2026 Earnings Call Transcript

NRXP Q1 2026 Earnings: Revenue-less Biotech Reports EPS Miss but Stock Surges 34% - Analyst Consensus Shift

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update